New Two-Year CRENESSITY Data Show Durable Hormone Control and Clinical Improvements in Pediatric CAH, Supporting Commercial Thesis

What happened

Neurocrine presented two-year data from the Phase 3 CAHtalyst Pediatric study, demonstrating that CRENESSITY provides durable androgen control and sustained reductions in ACTH and 17-OHP while enabling lower, more physiologic glucocorticoid doses. Notably, 60% of overweight/obese patients experienced clinically meaningful BMI improvements, and 61% of those with baseline insulin resistance were no longer insulin resistant after two years. These data reinforce CRENESSITY's value proposition as a disease-modifying therapy in classic CAH, addressing both hormonal control and long-term glucocorticoid toxicity. The results come ahead of Neurocrine's planned April 2026 field expansion for CRENESSITY, which aims to broaden prescriber depth beyond early adopters. While the data are clearly positive, the key commercial test remains whether repeat-writing density per prescriber increases post-expansion, translating clinical efficacy into sustained revenue growth.

Implication

The durable two-year outcomes strengthen the drug's differentiation and provide ammunition for payer discussions, potentially supporting gross-to-net discipline (~20% guided). However, the pipeline beyond these two products is thin, and the DOJ CID overhang remains. Investors should monitor CRENESSITY new-prescription trends and prescriber breadth in Q3 2026 as the key proof point for the commercial ramp.

Thesis delta

The news does not change the fundamental thesis but de-risks the CRENESSITY commercial case by providing strong long-term efficacy and safety data that should facilitate prescriber adoption and payer coverage. The thesis delta is an increased confidence in CRENESSITY's ability to scale, moving it from a promising launch to a validated growth driver, which supports the bull case scenario. However, the overall conviction remains tied to INGREZZA net price stability and the DOJ outcome.